The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequency of MET amplification determined by comprehensive next-generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors.
Norma Alonzo Palma
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Gary A. Palmer
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Siraj M. Ali
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Philip J. Stephens
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Jeffrey S. Ross
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Vincent A. Miller
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Doron Lipson
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine